ライフサイエンスコーパス: liver function test

1 in the 0.9% sodium chloride group (abnormal liver function test).

2 s (all liver transplant patients with normal liver function tests).

3 monly used blood tests (full blood count and liver function tests).

4 ts to withdraw steroid resulted in a rise in liver function test.

5 Serologic, histologic, and liver function tests.

6 ad jaundice and markedly abnormal results on liver function tests.

7 e (SARS), many patients had abnormalities in liver function tests.

8 alongside elevated inflammatory markers and liver function tests.

9 ts were assessed by pure tone audiometry and liver function tests.

10 up to 109/mL) lasting 5--6 days and abnormal liver function tests.

11 Blood was drawn for leukocyte counts and liver function tests.

12 significantly higher in those with abnormal liver function tests.

13 nosis, were well and had normal results from liver function tests.

14 ischemia was determined by survival time and liver function tests.

15 d graft outcome than any of the conventional liver function tests.

16 concentrations, hematological profiles, and liver function tests.

17 e drained and resolved with normalization of liver function tests.

18 lantation, presenting as ascites with normal liver function tests.

19 ls within the liver at this stage and normal liver function tests.

20 Most patients had normal liver function tests.

21 e liver were highly correlated with clinical liver function tests.

22 ted using regular monitoring of hemogram and liver function tests.

23 age over previously studied dose metrics and liver function tests.

24 stasis had abnormal findings on simultaneous liver function tests.

25 amination to her family doctor with abnormal liver function tests.

26 ic control, blood pressure, lipid tests, and liver function tests.

27 uence postoperative AST peak values or other liver function tests.

28 difference was found in other postoperative liver function tests.

29 vity of liver disease, which is reflected by liver function tests.

30 te dehydrogenase (LDH), 397 IU/L; and normal liver function tests.

31 a, vomiting, fatigue, alopecia, and elevated liver-function tests.

32 pyrexia, somnolence, and abnormal results on liver-function tests.

33 , ABO blood group matching, and preoperative liver function testing.

34 diarrhea (35%), anemia (18%), and increased liver function tests (12%).

35 Inclusion criteria were liver function tests 2.5 times the upper limit of normal

36 ting for ECD-liver status included: elevated liver function tests (20%), hypernatremia (12.6%), and e

37 mas (34 [10%]), rash (30 [9%]), and abnormal liver function tests (38 [11%]) in the vemurafenib group

38 bleeding (17/38), ascites (6/38), increased liver function tests (6/38), splenomegaly (5/38), or scr

39 Patients underwent endoscopy, liver biopsy, liver function tests, abdominal ultrasonography, a detai

40 two patients at that dose level) and grade 4 liver function test abnormalities (in one patient).

41 olated Ductular Hyperplasia in patients with liver function test abnormalities and other topics with

42 Liver function test abnormalities are common in patients

43 uate the frequency, pattern, and severity of liver function test abnormalities in patients with Lyme

44 Neutropenia, peripheral edema, and liver function test abnormalities were dose-limiting at

45 viduals with no other identifiable cause for liver function test abnormalities who presented with EM

46 ea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect

47 luated by physiologic monitoring, changes in liver function tests, adverse events, and radiopharmaceu

48 the percentage of patients with any abnormal liver function test after baseline sampling was similar

49 ctive framework to identify MetS using serum liver function tests-Alanine Transaminase (ALT), Asparta

50 as determined by body mass index (BMI), and liver function tests (ALT, AST, and GGT) in a random sam

51 ALT) (27%) were the most frequently elevated liver function tests among Lyme disease patients.

52 The liver function test and histological study revealed mini

53 7 controls, up to 1 million individuals with liver function tests and a validation cohort of 21,689 c

54 Renal and liver function tests and biopsies revealed a lack of nep

55 erative [POD] day 21) was proven by elevated liver function tests and biopsy.

56 temic hemodynamics were measured, along with liver function tests and clinical outcomes.

57 Monitoring was by liver function tests and coagulation parameters.

58 Liver function tests and histology revealed only minor p

59 Correlations between liver function tests and imaging markers were performed

60 cases (5%) of mild to moderate elevations of liver function tests and no QTc prolongations.

61 The patient had a past history of abnormal liver function tests and previous biopsy-proven steatosi

62 e events, the most common being elevation of liver function tests and pyrexia, most of which resolved

63 Liver function tests and synthetic function were monitor

64 ll tolerated, with only modest elevations of liver function tests and thrombocytopenia, each being ob

65 re cohort, these miRNAs were correlated with liver function tests and were independent predictors of

66 ing lipid profile, fasting glucose, insulin, liver function tests) and abdominal ultrasound with fibr

67 rgery; including improved metabolic profile (liver function tests), and shorter ICU stay.

68 ing complete blood cell count, electrolytes, liver function tests, and creatinine level).

69 iochemical markers, including lipid profile, liver function tests, and CRP (as marker of inflammation

70 chimerism, recipient immune reconstitution, liver function tests, and graft survival were determined

71 mptoms-which include fever, anemia, elevated liver function tests, and hemoglobinuria-may be especial

72 g on CsA, whereas thrombocytopenia, abnormal liver function tests, and hypokalemia were reported more

73 aspofungin) local phlebitis, fever, abnormal liver function tests, and mild haemolysis.

74 acteristics, including pretreatment history, liver function tests, and PET/CT parameters, were assess

75 NA, HCV genotype (nucleic acid tests [NAT]), liver function tests, and platelet counts; patient age w

76 ase score, pre- and post-DIPS PSGs, pre-DIPS liver function tests, and pre-DIPS creatinine levels.

77 ic, pancreatitis, unexplained derangement of liver function tests, and/or dilated CBD without an iden

78 A full blood count; liver function test; and measurements of urea and electr

79 Asymptomatic patients with abnormal liver function tests are common in the lipid clinic, and

80 Although the liver function tests are elevated in an organ donor, the

81 Chest x-rays, CBCs, and liver function tests are not recommended, and molecular

82 We further discuss the use of liver function tests as prognostic markers in patients w

83 y seems to be the most valuable quantitative liver function test, as it can measure multiple aspects

84 fections (UTIs), total caloric delivery, and liver function tests (aspartate aminotransferase, alanin

85 No grade >1 alterations in liver function tests associated with CV706 administratio

86 A uniform policy of liver function testing at 2 weeks is useful for prompt i

87 recorded indications for ultrasonography and liver function tests at diagnosis, management of HAT, an

88 Our study included 602 IBD patients, with liver function tests at regular intervals.

89 Of these women 49% had normal liver function tests at the time of survey, 33% mildly a

90 patients with liver dysfunction [>/= grade 2 liver function tests] at greater risk).

91 l individuals have complete normalization of liver function testing between episodes.

92 No changes in liver function tests between treatment arms were observe

93 animal survival, hepatic tissue blood flow, liver function tests, blood and tissue biochemistry, and

94 d a rash and another had elevated results on liver-function tests; both of these effects resolved wit

95 of a common duct stone (including increased liver function tests but bilirubin <4 mg/dL and no chola

96 ucose to the rat donors affected outcome and liver functions tested by isolated perfusion after 24- a

97 w-up data consisted of physical examination, liver function tests, CEA, chest X-ray, computed tomogra

98 standardized GI symptoms questionnaires and liver function test checks on admission to better quanti

99 require rethinking our definition of "normal liver function tests." Chronic viral hepatitis B and C r

100 monitoring, including toxicology screening, liver function tests, coagulation studies, serum chemist

101 For individuals with abnormal liver function tests, common causes of hepatitis, includ

102 ur more frequently in patients with elevated liver function tests compared with those with normal val

103 ass index (BMI), HBV DNA level, HBsAg level, liver function test, complete blood count, aspartate ami

104 Liver function tests decreased from baseline to end of t

105 tly greater (P < 0.05) incidence of abnormal liver function tests, diarrhea, hypokalemia, and thrombo

106 platelet count, serum creatinine level, and liver function tests did not change significantly from b

107 However, traditional liver function tests do not provide quantitative data ab

108 Seven patients experienced a rise in liver function tests during the period of increased ster

109 Grade 3/4 toxicities included liver function test elevation (14%), pneumonitis (9%), d

110 -4 adverse events were neutropenia (58%) and liver function test elevation (17%).

111 nts were nausea, edema, confusion, diarrhea, liver function test elevation, fatigue, and myalgia.

112 ade 3 to 4 toxicities consisted primarily of liver function test elevations (24%), nausea/vomiting (1

113 ters are associated with mithramycin-induced liver function test elevations, and the present results

114 n (EAA) using clinical biomarkers, including liver function test enzymes (LFTs) and clinical measures

115 sical examination, complete blood count, and liver function tests every 3 months and a chest radiogra

116 Adverse events included abnormalities in liver-function tests, fatigue, nausea, headache, dizzine

117 Unit (ICU) and hospital stay, postoperative liver function tests, fatty acid and eicosanoid concentr

118 serum erythrocyte protoporphyrin levels and liver function tests following treatment were assessed.

119 inhibitor dose reduction by 75% with stable liver function tests for at least 12 weeks.

120 of intraoperative biopsies and postoperative liver function tests for the development of preservation

121 NE search was performed using the key words "liver function tests," "functional studies in the liver,

122 n for full blood count, HBV antigen profile, liver function tests, HBV DNA quantification and cytokin

123 The blood tests performed included liver function tests, HBV serologies, and HBV genotyping

124 al adiposity, lipid profile, blood pressure, liver function tests, homeostatic model assessment for i

125 , was compared with the MVM's based on other liver function tests (ICG clearance, ALICE) by comparing

126 s based on more expensive and time-consuming liver function tests (ICG clearance, ALICE), the APRI+AL

127 sistance, serum ferritin, lipid profile, and liver function tests improved irrespective of bloodletti

128 After antibiotic treatment, elevated liver function tests improved or resolved in most patien

129 ept for apparently reversible alterations in liver function tests in approximately 6% of subjects, al

130 Elevated liver function tests in CFTR-knockout kits were correcte

131 Morphologic studies at necropsy and liver function tests in dogs receiving hemoglobin soluti

132 ere presentation and persistent elevation of liver function tests in many.

133 The results of liver function tests in the naltrexone group were simila

134 ied secondary outcomes, including adiposity, liver function tests, incidence of conjugated hyperbilir

135 al blood counts, electrolytes, and renal and liver function tests (including lactic acid dehydrogenas

136 Passive liver function tests, including biochemical parameters a

137 had increased serum HA and FIB-4 related to liver function tests, inflammatory markers, and blood ox

138 NAFLD can be asymptomatic, with liver function tests insensitive to mild disease, and li

139 indices with the severity of liver disease, liver function tests, insulin growth factor-1 (IGF-1) an

140 Postoperative liver function tests, intensive care unit stay, hospital

141 h reversible, elevated liver enzymes; hence, liver function testing is needed to identify those unsui

142 Liver function test (LFT) elevations occurred in 10% vs

143 Treatment records including liver function test (LFT) results at baseline and during

144 Five (15%) patients had liver function test (LFT) results that were more than ei

145 dence of NASH in all patients, regardless of liver function test (LFT) values, provided that they had

146 ife follow-up schedule including hepatic US, liver function tests (LFT), and a confirmatory CT/MRI.

147 Abnormal liver function tests (LFTs) are reported frequently in h

148 Although liver function tests (LFTs) are routinely measured in pr

149 ings for hepatotoxicity and required monthly liver function tests (LFTs) as part of a risk evaluation

150 t is unclear whether fat mass, lean mass, or liver function tests (LFTs) show similar attenuations.

151 each case, a point of acute deterioration in liver function tests (LFTs) was identified ("start time"

152 ociated with elevated liver enzyme levels on liver function tests (LFTs), and there were higher conce

153 able disease measures, including skin score, liver function tests (LFTs), blood counts, and lung func

154 ther symptom-based screening, screening with liver function tests (LFTs), HCV antibody (Ab) screening

155 ture resolution, improvement in symptoms and liver function tests (LFTs), stricture recurrence and co

156 l were on tacrolimus monotherapy with normal liver function tests (LFTs).

157 penia, thrombocytopenia, and mildly elevated liver function tests (LFTs).

158 om a brain-death donor was declined for high liver function tests (LFTs).

159 (IBD) are frequently associated with altered liver function tests (LFTs).

160 the extent of IRI were assessed by measuring liver function tests, lipid peroxidation, and metallopro

161 Liver function tests, lipid profiles, and stereological

162 no or minimal hepatic injury who had normal liver function tests (LTs) (referred to herein as the no

163 was systemic, manifested as an elevation in liver function tests, malaise, and edema.

164 Elevations in liver function tests (more than three times normal), all

165 the suitability for transplantation included liver function tests, morphologic and histologic assessm

166 burden of >900 mg/kg, marked improvement in liver function tests, much less neurodegeneration, and,

167 presenting with ascites (n = 10), increased liver function tests (n = 2), and splenomegaly (n = 2).

168 cholangiography, liver biopsy, and/or serial liver function tests (n = 38).

169 (N = 373) of 709 patients based on abnormal liver function tests, neutropenia, history of IV drug us

170 Liver function tests, nitrite + nitrate (NOx) and plasma

171 luzole was well tolerated; mean increases in liver function tests occurred but drug discontinuation w

172 Only mild and transient elevation of liver function tests occurred in 4 of 15 dogs.

173 , weight, liver size, blood lipids and blood liver function tests of the subjects were measured.

174 in patients with prolonged abnormalities of liver function tests of uncertain origin.

175 ostoperative complications, or perioperative liver function tests on liver regeneration.

176 e patient has subsequently maintained normal liver function tests on low-dose prednisone alone, with

177 ho are taking statins, routine monitoring of liver function tests or muscle enzymes is not recommende

178 (SNPs) near 7 loci have been associated with liver function tests or with liver steatosis by magnetic

179 , serious adverse events related to abnormal liver function tests (OR 11.19, 95% CI: 2.09-60.02) or p

180 c profile (OR, 0.78; 95% CI, 0.60-1.00), and liver function tests (OR, 0.72; 95% CI, 0.53-0.99) than

181 is (stage >or= 3), with histologic analysis, liver function tests, or MR imaging as the reference sta

182 ) developed symptoms of PBC and 24 (83%) had liver function tests persistently showing cholestasis.

183 hanges in blood chemistry (glucose, lactate, liver function tests, prothrombin time) and to assess li

184 We measured disease severity by quantitative liver function tests (QLFTs) to determine cutoffs for QL

185 MRCP + metrics correlated significantly with liver function tests (range 0.29 R 0.43, p < 0.05).

186 cT1 was significantly correlated with liver function tests (range 0.33 R 56, p < 0.05), as wel

187 latelet counts, serum creatinine values, and liver function tests remained normal in all animals rece

188 eatment, all patients had improved or normal liver function tests, resolution of C4d deposition and s

189 d body mass index, glycated haemoglobin, and liver function tests, respectively, before they were dia

190 f anemia, neutropenia, thrombocytopenia, and liver function test result abnormalities during chemothe

191 finitely related to the study drug: abnormal liver function test results (n=1), prolonged QT interval

192 Symptoms were: elevated liver function test results (serum glutamic oxaloacetic

193 biliary cirrhosis (PBC), but who had normal liver function test results and no symptoms of liver dis

194 tion of serum aminotransferase levels; other liver function test results are usually normal.

195 er disease was found to have mildly deranged liver function test results as part of his annual hypert

196 of symptoms, body mass index, calcium level, liver function test results before and at symptom onset,

197 ong 576 known variants associated with these liver function test results in the general population, U

198 Three volunteers had abnormal liver function test results temporally associated with i

199 Clinical evaluation and assessment of liver function test results were done daily during hospi

200 Thyroid and liver function test results were normal, but she had rap

201 results, including complete blood count; and liver function test results were normal.

202 results, including complete blood count; and liver function test results were normal.[Figure: see tex

203 Liver function test results were within normal limits.

204 er, white blood cell count, bilirubin level, liver function test results) was conducted by reviewing

205 anorexia, constipation, dizziness, elevated liver function test results, fever, headache, heartburn,

206 ated with patient survival, acute rejection, liver function test results, recurrence of viral or othe

207 cose, and lipid levels, insulin sensitivity, liver function test results, waist circumference, blood

208 th associated complete blood count (CBC) and liver function test results, were retrospectively review

209 p discontinued the study because of elevated liver function test results.

210 g, and/or diarrhea, and 3 developed abnormal liver function test results.

211 s investigated for liver disease or abnormal liver function test results.

212 Liver injury ranged from abnormal liver-function test results to rapidly progressive and f

213 Histology studies and liver function tests reveal that no apparent toxicity is

214 Postoperative liver function testing revealed significant early differ

215 e levels were within normal limits; however, liver function tests revealed a mildly elevated alanine

216 e levels were within normal limits; however, liver function tests revealed a mildly elevated alanine

217 Liver function tests revealed severe hepatocellular inju

218 y periodic surveillance with hepatic USG and liver function tests scheduled every 6 months for the fi

219 Liver function tests, serum electrolytes, and cholestero

220 Neutropenia, elevated liver-function tests, serum creatinine elevations and li

221 Patients with XHIM who have abnormal liver function tests should be considered at increased r

222 computed tomography volumetry, quantitative liver function tests should be used to determine whether

223 Liver function tests showed higher levels of aspartate a

224 rmal baseline liver function (n = 49 [47%]), liver function tests significantly improved from baselin

225 All seven patients had normal liver function tests, skin rash, and diagnosis of GvHD h

226 Associations with abnormal liver function tests, somnolence, sedation and pneumonia

227 Dynamic quantitative liver function tests, such as the indocyanine green test

228 dity score, and medications that can elevate liver function tests sufficiently to necessitate discont

229 ing EVG/COBI/FTC/TDF had abnormal results in liver function tests than did those receiving ATV/RTV+FT

230 Reversible increases in liver function tests, thrombocytopenia, anemia and fatig

231 nifestations from asymptomatic elevations of liver function tests to hepatic decompensation.

232 Four (14.2%) had modest elevations in liver function tests (two biopsy proven mild rejections

233 iver volumes, radiation doses, and serologic liver function tests (unpaired t test, P = 0.05) and 2)

234 blood count, glomerular filtration rate, and liver function test were obtained at baseline and on fol

235 ow in the HM was lower than in controls, and liver function tests were abnormal.

236 Liver function tests were assessed monthly.

237 Trajectories of serum liver function tests were assessed over time using mixed

238 ences of PHP and stroma-free hemoglobin with liver function tests were determined and recommendations

239 egorized with NAFLD Activity Score (NAS) and liver function tests were done before surgery and after

240 iate for paclitaxel therapy who had abnormal liver function tests were eligible.

241 in samples preceding AR versus non-AR, when liver function tests were normal, and decreased followin

242 mphocytes, monocytes, platelets, D-dimer and liver function tests were observed 24 to 48 hours after

243 cant changes in triacylglycerol, glucose, or liver function tests were observed with Sterol Bev.

244 Liver function tests were performed.

245 om mutant and control mice were examined and liver function tests were performed.

246 spected acute gallstone disease and abnormal liver function tests were randomized into two diagnostic

247 Liver function tests were repeated after portal pumping.

248 At EOP, liver function tests were similar but creatinine clearan

249 n site reactions and transient elevations of liver function tests were the most notable side effects.

250 Liver histology and liver function tests were unaffected in transgenic anima

251 isone, and nausea, fatigue, and any abnormal liver-function test were among the most common adverse e

252 tes of infection, rash, and abnormalities on liver-function testing were higher with daclizumab HYP t

253 -related adverse events and abnormalities on liver-function testing were more common with abiraterone

254 thromboses, deaths, or persistent changes in liver-function tests were observed.

255 mple values (for chemistry, hematologic, and liver function tests) were checked at regular intervals

256 Reliance on abnormal liver function tests will miss most patients with signif

257 y artery stenosis, persistent rash, elevated liver function tests with drug-induced fatty liver, atri

258 imary care initiated strategies: (1) routine liver function tests with follow-up ultrasonography for

259 nn-Whitney U tests were performed to compare liver function tests with imaging markers between patien

260 Normalization of liver function tests with improvement in viremia was ach

261 -10 x10(9)/L), and an obstructive pattern on liver function tests, with a total bilirubin level of 3.